The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. by Seipel, Katja et al.
cancers
Article
The Cellular p53 Inhibitor MDM2 and the Growth
Factor Receptor FLT3 as Biomarkers for Treatment
Responses to the MDM2-Inhibitor Idasanutlin and
the MEK1 Inhibitor Cobimetinib in Acute
Myeloid Leukemia
Katja Seipel 1,2,*, Miguel A. T. Marques 1, Corinne Sidler 1, Beatrice U. Mueller 2 and
Thomas Pabst 2,*
1 Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland;
Miguel.Teixeiramarques@students.unibe.ch (M.A.T.M.); Corinne.Sidler@dbmr.unibe.ch (C.S.)
2 Department of Medical Oncology, University Hospital Bern, 3010 Bern, Switzerland;
Beatrice.Mueller@insel.ch
* Correspondence: katja.seipel@dbmr.unibe.ch (K.S.); thomas.pabst@insel.ch (T.P.)
Received: 13 April 2018; Accepted: 29 May 2018; Published: 31 May 2018


Abstract: The tumor suppressor protein p53 is inactivated in a large variety of cancer cells.
Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53
function in acute myeloid leukemia (AML). Moreover, fms like tyrosine kinase 3 (FLT3) growth factor
signaling pathways including the mitogen-activated kinase (MAPK) cascade (RAS-RAF-MEK-ERK)
are highly active in AML cells. Consequently, the combined administration of MDM2 and MEK
inhibitors may present a promising anti-leukemic treatment strategy. Here we assessed the MDM2
antagonist idasanutlin and the MEK1 inhibitor cobimetinib as single agents and in combination in
a variety of AML cell lines and primary AML blast cells for their ability to induce apoptosis and cell
death. AML cell lines and blast cells comprised all major AML subtypes based on the mutational
status of TP53, FLT3 and NPM1 genes. We observed a considerably varying anti-leukemic efficacy of
idasanutlin and cobimetinib. AML cells with high sensitivity to the single compounds as well as to
the combined treatment emerged with normal karyotype, wild-type TP53 and elevated FLT3 and
MDM2 protein levels. Our data indicate that AML cells with normal karyotype (NK) and wild-type
status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined
treatment with cobimetinib and idasanutlin. FLT3 and MDM2 are biomarkers for treatment response
to idasanutlin and cobimetinib in AML.
Keywords: acute myeloid leukemia (AML); FMS like tyrosine kinase 3 (FLT3); tumor suppressor
p53 (TP53); mouse double minute 2 homolog (MDM2); mitogen-activated protein kinase kinase
(MEK; MAP2K; MAPKK)
1. Introduction
Based on its fundamental role in induction of cell cycle arrest and apoptosis there is tight regulation
of the function of the tumor suppressor p53 in normal cells. In tumor cells, however, the p53 function
is frequently inactivated enabling evasion of growth control and outgrowth of malignant cells. In acute
myeloid leukemia (AML), the p53 function is rarely disrupted by TP53 gene mutations, but more often
by dysregulation of the nucleolar phosphoprotein nucleophosmin (NPM1) [1], the cellular p53 inhibitor
MDM2 [2], the nuclear export protein XPO1/CRM1 [3], or the cytoplasmic retention protein
CUL9/PARC [4]. While the NPM1 gene is commonly mutated in AML, the protein levels of MDM2,
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XPO1 and CUL9 are frequently elevated in AML cells [5]. In addition to p53 inactivation, there may be
activation of oncogenes in the leukemic cell. A key oncogene in AML is the FMS-kinase 3 (FLT3) gene.
This growth factor receptor is overexpressed in the majority of AML cells [6] or constitutively active in
AML cells with FLT3 mutation, observed in up to 30% of AML patients [7]. FLT3 receptor signaling
promotes cell survival and prevents apoptosis via activation of the PI3K-PDK1-AKT kinase cascade
and via RAS GTPases to the MAP kinase cascade (MEK-ERK-MNK) [8,9]. FLT3-ITD is a constitutively
active FLT3 receptor signaling via PI3K-PDK1-AKT, via RAS-RAF-MEK-ERK and via STAT5 [10].
Kinase function can readily be blocked and a number of kinase inhibitors with varying specificity
for kinases including the FLT3 and MAP kinases are being tested in preclinical and clinical cancer
trials [7,11].
Idasanutlin is an MDM2 inhibitor which has been tested in preclinical studies in solid
tumors [12,13] and in hematological malignancies including AML [14]. Cobimetinib is a highly selective
MEK1 inhibitor studied as a targeted therapy in BRAF and NRAS mutant melanoma [15], and it has
been tested in preclinical studies in NRAS mutant AML [16]. In this study, we investigated both the
MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib in AML cells in order to identify
a potentially effective treatment for subgroups of AML patients unfit for intensive chemotherapy.
The study might provide the rationale for initiating a clinical study in TP53wt NK AML evaluating
this treatment combination.
2. Results
2.1. Synergistic Effects on Cell Viability in AML Cell Lines Treated with the MDM2 Inhibitor Idasanutlin and
the MEK Inhibitor Cobimetinib
To determine the sensitivity of AML cells to idasanutlin and cobimetinib we tested the cell viability
of a variety of AML cell lines in in vitro cytotoxicity assays. The cell lines covered the major molecular
AML subtypes characterized by the FLT3-ITD and FLT3 wild type, NPM1 mutant and wild type,
TP53 mutant and wild type as well as RAS mutant and wild type genes (Table 1).
Table 1. Acute myeloid leukemia (AML) cell lines and patient samples
ID FLT3 TP53 Mutated Genes
OCI-AML2 wt/A680V wt DNMT3A
FLT3wt-S (5) wt wt NPM1 (3) NRAS (1)
MOLM-13 ITD wt MLL-AF9 mTOR
FLT3-ITD-S (7) ITD wt NPM1 (4)
MV4-11 ITD wt MLL-AF4
FLT3-ITD-R (6) ITD wt NPM1 (2) RUNX1 (2)
PL-21 wt/P336L wt/P36fs KRAS
HL-60 wt del NRAS
FLT3wt-R (5) wt wt NPM1 (2) DNMT3A (1)
MOLM-16 wt mut MLL V1368L
TP53mut (3) wt mut PTPN11 (1) NRAS (1)
AML cell lines (grey) and AML patient samples (white); grouped according to FLT3 and TP53 status and response
to combination treatment (number of samples).
We observed considerable differences in the AML cells lines with respect to idasanutlin and
cobimetinib sensitivity (Figure 1A,B). MOLM-13 (FLT3-ITD) cells were most sensitive to idasanutlin
with 50% loss of cell viability to 0.5 µM idasanutlin in 24 h. At 10 µM idasanutlin, MV4-11 (FLT3-ITD)
and OCI-AML2 (FLT3wt) had 50% loss of cell viability whereas OCI-AML3 (FLT3wt), PL-21 (FLT3-ITD)
and MOLM-16 (TP53mut) cells only lost 10% of cell viability. With respect to cobimetinib OCI-AML2
(RASwt), PL-21 (KRASmut), HL-60 (NRASmut) and OCI-AML3 (NRASmut) cell lines were susceptible
to a 30% loss of cell viability to 150 nM cobimetinib in 24 h. At 1 µM cobimetinib, MOLM-13
(RASwt) cells had 20% loss of cell viability while MV4-11 (RASwt) and MOLM-16 (RASwt) cells
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only lost 10% of cell viability. To determine the optimal regime for combination treatments we
tested the effects of sequential versus direct combination treatment with idasanutlin and cobimetinib.
Sequence of application was not important as idasanutlin pretreatment followed by cobimetinib
treatment had the same effect on cell viability as cobimetinib pretreatment followed by idasanutlin
treatment. Moreover, both sequential treatments had nearly the same effect on cell viability as
direct combination treatment (Figure S1). In the direct combination treatment with idasanutlin and
cobimetinib, we again observed considerable differences in the responses of the tested AML cell lines
(Figure 1C). OCI-AML2, MV4-11, MOLM-13, PL-21 and OCI-AML3 cells showed synergistic responses
with combination indexes of 0.1, 0.15, 0.3, 0.55 and 0.8, respectively (Figure 1D–F). The addition of
idasanutlin did not lead to an enhanced cytotoxic response of TP53 deficient HL-60 cells to cobimetinib
and TP53 mutant MOLM-16 cells were resistant to both compounds in the tested concentrations
(Figure 1C). In summary, OCI-AML2 cells were susceptible to idasanutlin and cobimetinib as single
compounds with strong synergistic effects in the combined treatment. Susceptibility of MOLM-13
and MV4-11 cells was substantial towards idasanutlin, but marginal to cobimetinib, with synergistic
effects in the combination treatment. Susceptibility of RAS mutated cells PL-21 and OCI-AML3 was
substantial towards cobimetinib, but marginal to idasanutlin, with moderate synergistic effects in the
combination treatment. With substantial reduction of cell viability in sensitive AML cell lines at 0.5 to
1 µM idasanutlin and 50 to 100 nM cobimetinib, we chose to test molecular effects in AML cell lines
treated at these concentrations of inhibitors.
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Figure 1. Sensitivity of AML cells to idasanutlin and cobimetinib. Cell viability in AML cell lines
treated for 24 h with increasing dosages of idasanutlin (A) or cobimetinib (B) or in direct combination
(C). Dose-effect curves in OCI-AML2 (D), MV4-11 (E) and MOLM-13 cells (F) treated with idasanutlin
and cobimetinib alone or in combination. Fa indicates fraction of affected cells. Combination indexes
were calculated on compusyn software (version 1.0; ComboSyn, Inc. Paramus, NJ, USA).
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2.2. Inhibition of Cell Cycling and Induction of Apoptosis by Idasanutlin and Cobimetinib
To confirm p53 activation by MDM2 inhibition we determined the expression levels of the tumor
suppressor protein p53, of the activated acetylated p53 protein and of the p53 target gene CDKN1A in
AML cells treated for 24 h with single compounds and with combined treatment. Protein p53 levels
were rather high in untreated OCI-AML2 cells with a 50% increase of protein level and a three-fold
induction of acetylated p53 in idasanutlin treated cells (Figure 2A). MOLM-13 protein p53 levels were
induced three-fold and acetylated p53 levels over ten-fold in idasanutlin treated cells (Figure 2B).
Moreover, there was a four-fold p53 protein induction in idasanutlin treated MV4-11 cells (Figure S2)
confirming that p53 activation is a general consequence of treatment with the MDM2 inhibitor
idasanutlin. CDKN1A gene expression was induced six-fold in OCI-AML2 (Figure 2C), twelve-fold
in MOLM-13 cells treated with 1 µM idasanutlin (Figure 2D) and ten-fold in MV4-11 (Figure S2).
Interestingly, there was also an induction of CDKN1A expression in OCI-AML2 and MV4-11 cells
treated with 50 nM cobimetinib, but not in MOLM13 cells, indicating that MEK inhibition can lead to
p53 activation, at least in some AML cells. Acetylated p53 levels were maximal in AML cells treated
with combinations of idasanutlin and cobimetinib. CDKN1A expression was induced five-fold in
OCI-AML2, sixteen-fold in MOLM-13 and MV4-11 cells, indicating a negative effect of cobimetinib on
the idasanutlin induced CDKN1A gene expression in OCI-AML2 cells and a positive effect in MOLM-13
and MV4-11 cells. Indeed the combination index for the effect of the combined treatment on CDKN1A
expression was calculated at 1.6 in OCI-AML2 cells confirming an antagonistic effect of cobimetinib on
idasanutlin induced CDKN1A expression, and 0.8 in MV4-11 cells indicating a moderate synergistic
effect in this context.
To demonstrate the induction of cell cycle arrest in AML cells with elevated levels of the cell
cycle inhibitor CDKN1A, the cell cycle was analyzed by DNA content measurement employing flow
cytometry in OCI-AML2 (Figure 2E and Figure S4A) and MOLM-13 cells (Figure 2F and Figure S4B)
treated with single compounds or combined treatment. As treatments with 1 µM idasanutlin and
50 nM cobimetinib induced substantial cell death in the in vitro cytotoxicity assays, we applied the
compounds at lower concentrations in the flow cytometry assays. This entailed treating OCI-AML2
cells with 100 nM idasanutlin and induced cell cycle exit and cell death illustrated by an increase
of resting cells (G0) from 10% to 20% and an increase of dead cells (sub-G1) from 8% to 18% with
a concomitant reduction in the proliferating cells (S and G2) (Figure 2C). Treating OCI-AML2 cells
with 50 nM cobimetinib had similar effects with a greater emphasis on cell cycle exit and minor
induction of cell death. Compared to single compounds, idasanutlin and cobimetinib together led
to a further increase in cell cycle exit and cell death, with over 30% resting and over 30% dead cells
with concomitant reduction in proliferating cells (G1, S and G2). In contrast to OCI-AML2 cells, 50 nM
cobimetinib had no effect on MOLM-13 cells, whereas idasanutlin treatment led to an 11% increase
in G1 and a 4% increase in G0 phase cells with a concomitant reduction of S- and G2-phase cells
indicating G1cell cycle arrest (Figure 2D). The same 24 h treatment with idasanutlin led to a G1 arrest
in MOLM-13 cells, and an increase of G0 and subG1 fractions in OCI-AML2 cells. As cells exit the
cycle at G1 to enter G0, the increase in G0 and subG1fractions in OCI-AML2 was necessarily preceded
by a G1 arrest. Compared to MOLM-13 OCI-AML2 cells showed a faster response in the induction of
G1 arrest and cell cycle exit.
In addition to CDKN1A induction, p53 activation due to MDM2 or MEK inhibition also led to
reduced phosphorylation of eIF4E, BAX gene induction, MCL1 gene repression and eventually to
cell death by apoptosis. Differences in eIF4E phosphorylation and in apoptotic DNA fragmentation
were detectable only at higher concentrations of cobimetinib. The levels of phosphorylated eIF4E
fell from 26% to 17% in MOLM-13 cells treated with 1 µM idasanutlin or 1 µM cobimetinib with
the lowest levels of 13% in the combined treatment (Figure 3A). The pattern of fragmented DNA
typical for apoptosis and a concomitant reduction of the amount of intact genomic DNA was present
in MOLM-13 cells treated with 0.5 µM idasanutlin or 0.5 µM cobimetinib, with greatest reduction
in the combined treatment, again indicating a synergistic effect of idasanutlin and cobimetinib on
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apoptosis induction (Figure 3B). MCL1 gene expression in the 1 µM idasanutlin treated cells was
at 75% compared to control DMSO treated cells, at 90% in the 50 nM cobimetinib treated cells and
at 55% in the combination treatment (Figure 3C). With a combination index of 0.45 the inhibitory
effect of cobimetinib and idasanutlin on MCL1 gene expression in MOLM-13 cells appeared to be
synergistic. There was induction of BAX gene expression and caspase 3/7 activities in MOLM-13
and OCI-AML2 cells treated with idasanutlin, with further induction in combination treated cells
(Figure 3D,E, Figures S3A and S5A). There was a dose dependent increase in the number of annexin
positive cells in MOLM-13 and OCI-AML2 cells treated with idasanutlin and cobimetinib (Figure 3F,
Figures S3B and S5B). The maximum number of annexin positive cells was present after combined
treatment indicating a synergistic effect of idasanutlin and cobimetinib on apoptosis induction.
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Figure 2. Induction of cell cycle arrest, c ll cycle exit and cell eath in AML cells treated with idasanutlin
and cobimetinib. Induction of tumor suppressor protein p53 in OCI-AML2 (A) and MOLM-13 cells
(B) treated for 24 h with the indicated amounts of idasanutlin and cobimetinib. Induction of the
cell cycle inhibitor CDKN1A gene in OCI-AML2 (C) and MOLM-13 cells (D). Relative quantitation
of CDKN1A mRNA normalized to GAPDH. Data are presented as fold induction of treated versus
untreated, with CDKN1A expression in DMSO treated cells = 1. Induction of cell cycle arrest, cell cycle
exit and cell death in the AML cell lines OCI-AML2 (E) and MOLM-13 (F) treated for 24 h with single
compounds or with combination treatment. Cells were grouped into defined cell cycle phases by DNA
content and Ki-67 expression levels with subG1 (<2n), G0 (2n, Ki67 low), G1 (2n, Ki67 high), S (2n–4n),
and G2 (4n). Significance is denoted for p < 0.05 (*); p < 0.0005 (***); p < 0.0001 (****); p > 0.05 (ns).
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Figure 3. Induction of apoptosis in AML cells treated with idasanutlin and cobimetinib. Reduced levels
of activated translation initiation factor phospho-eIF4E (A), induction of apoptotic DNA fragmentation
(B), reduced mRNA levels of the apoptosis inhibitor MCL1 gene (C), i ced mRNA levels of the
pro-apoptotic BAX g ne (D), induced caspase 3/7 activity (E), increase in annexin positive apoptotic
MOLM-13 cells (F) treated with the indicated amounts of idasanutlin (idasa) and cobimeti ib (cob).
Cells were grouped into viable (annexin lo), early apoptotic (annexin med), and late apoptotic
(annexin h ) cells. Significanc is denoted for p < 0.05 (*); p < 0.005 (**).
In summary, these data suggest that AML cells treated with the MDM2 inhibitor idasanutlin
and the MEK1 inhibitor cobimetinib induced CDKN1A gene expression and cell cycle arrest,
cell cycle exit and cell death, reduced levels of activated eIF4E protein, induced BAX gene
expression, suppressed MCL1 gene expression, induced caspase3/7 activity and triggered apoptosis
as summarized in Figure 4. One or the other downstream effects might be preferentially induced in
different AML cells, depending on the differential activation of p53 by acetylation and methylation.
Acetylated p53 may have an increased ability to transcribe BAX, but not CDKN1A, resulting in
a preferential activation of the apoptotic pathway over cell cycle arrest, while methylated p53 may
have an increased ability to transcribe CDKN1A, resulting in a preferential induction of cell cycle
arrest [17,18].
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Figure 4. Schematic representation of the FLT3 signaling pathways and downstream effects. FLT3 is
a growth factor receptor signaling via PI3K-PDK1-AKT and via RAS-RAF-MEK-ERK leading to cell
growth and proliferation involving p53 inhibition. Idasanutlin and cobimetinib inhibit MDM2 and
MEK1 leading to reactivation of the tumor suppressor p53 and to induction of CDKN1A and BAX gene
expression as well as inhibition of MCL1 gene expression and in consequence to induction of cell cycle
arrest and apoptosis. FLT3-ITD is a constitutively active FLT3 receptor signaling via PI3K-PDK1-AKT,
via RAS-RAF-MEK-ERK and via STAT5.
2.3. Varying Sensitivity of AML Patient Cells to Treatment with the MDM2 Inhibitor Idasanutlin and the
MEK Inhibitor Cobimetinib
Considering the wide range of responses observed in AML cell lines to the combination treatment
with idasanutlin and cobimetinib, we hypothesized that susceptibility to this treatment would be
different among genetically defined AML subgroups. We performed in vitro cytotoxicity assays
using mononuclear cells isolated from peripheral blood or bone marrow of a small panel of AML
patients (Table 2). The blast cells covered the major molecular subtypes including FLT3-ITD and
FLT3 wild type, NPM1 mutant and NPM1 wild type, as well as TP53 mutant and TP53 wild type cells.
The majority of the blast cells carried wild type RAS genes with only two NRAS mutations present in
the twenty-seven samples.
Table 2. AML cohort study samples.
Clinical Characteristic bsolute u ber Relative Number (%)
AML 27 100
FAB classification
M0 0 0
M1 6 22
M2 7 26
3 0 0
4 6 22
8 30
0 0
0 0
Pathogenesis de novo 26 96
l 1 4
olecular nalysis
FLT3wt/NPM1wt 15 56
FLT3-ITD 12 44
P 1 ut 12 44
-I t 6 22
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Table 2. Cont.
Cytogenetic Analysis
normal karyotype (NK) 20 74
−5, −5q 0 0
−7, −7q 3 11
inv(16) 1 4
t(8;21) 0 0
t(15;17) 0 0
complex karyotype (CK) 3 11
Risk Category *
favorable 6 22
intermediate 6 22
adverse 15 56
* Favorable risk comprised t(8;21), t(15;17), inv(16) and NK with NPM1mut, FLT3-ITD negative; intermediate risk
comprised NK without mutations or with FLT3-ITD and NPM1mut; adverse risk comprised −5, −5q, −7, −7q,
NK with FLT3-ITD, complex karyotype.
The responses to idasanutlin and cobimetinib varied among the tested AML samples (Table S1).
In order to find correlations of response to genotype we initially grouped the NK-AML samples
according to FLT3 status. In grouped analysis, we observed that FLT3-ITD cells were more susceptible
to idasanutlin (Figure 5A) and less susceptible to cobimetinib (Figure 5B) compared to FLT3wt cells,
whereas there was no significant difference in the sensitivity towards the combination treatment in
FLT3wt and FLT3-ITD cells (Figure 5C). However, adding cobimetinib enhanced effects of idasanutlin
on FLT3wt cells (Figure 5D), but not on FLT3-ITD cells (Figure 5E).
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Figure 5. Effects of idasanutlin and cobimetinib t L patient and normal blood samples.
Cell viability asse sments in AML patient cel s treated f it idasanutlin and cobimetinib alone
or in combination are depicted for the genetic su r ing to the FLT3 status (A–E), for the
response ubgroups according to FLT3 status and sensiti i bination treatment (F), for the
response ubgroups FLT3wt-S (G), FLT3wt-R (H), FLT3ITD-S (I) and FLT3ITD-R (K). In our definition,
sensitive AML cells had less than 70% cell viability after 24 h treatment with 1 µM idasanutlin and
50 nM cobimetinib. * indicates significant p-values in Mann-Whitney test. AML blast cells were grouped
according to molecular subtypes (FLT3/TP53) and according to response rates. Normal samples were
grouped into peripheral blood mononuclear cells (PBM) and normal HSCs (CD34+). Significance is
denoted for p < 0.05 (*); p < 0.005 (**); p < 0.0005 (***); p < 0.0001 (****); p > 0.05 (ns).
Half of the AML samples were sensitive to idasanutlin, with less than 80% cell viability at
24 h treatment with 1 µM compound, comprising six FLT3wt and eight FLT3-ITD AML samples.
NPM1 status did not correlate to idasanutlin sensitivity as half of the FLT3wt and half of the FLT3-ITD
samples were the NPM1 wild type. In co trast to idasanutlin all AML cells includi g the TP53 mutated
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samples showed some response to cobimetinib, Nine AML samples were sensitive to cobimetinib with
less than 80% viability after 24 h treatment with 50 nM of the compound, of which six were FLT3wt,
one FLT3-ITD and two TP53 mutated AML.
Half of the AML samples were susceptible to the combination treatment with 1 µM idasanutlin
and 50 nM cobimetinib including five FLT3wt and seven FLT3-ITD NK-AML samples with 30% to
60% cell viability after 24 h treatment (Table S1). The other half of the AML samples were much
less affected by the combination treatment and included six FLT3-ITD and six FLT3wt NK-AML as
well as three TP53mut samples with complex karyotypes (Table S1). In order to define response
subgroups, the AML samples were separated into NK-AML and CK-AML and the NK-AML were
grouped according to FLT3 status as well as sensitivity to combination treatment (FLT3wt-S, FLT3wt-R,
FLT3ITD-S, FLT3ITD-R) (Figure 5F). Cells least affected by single agent and combination treatment
were normal peripheral blood monocytes and CD34 positive selected bone marrow cells. As in
OCI-AML2 cells, the response of FLT3wt-S AML patient cells to 1 µM idasanutlin was significantly
enhanced by the addition of 50 nM cobimetinib (Figure 5G). Similar to OCI-AML3 cells, FLT3wt-R
AML cells responded to cobimetinib (Figure 5H). Moreover, as in MOLM-13 cells, the addition of 50 nM
cobimetinib did not significantly enhance the response of FLT3-ITD-S patient cells to 1 µM idasanutlin
(Figure 5I) whereas FLT3-ITD-R patient cells showed minor response to both compounds (Figure 5K).
These data suggest that about half of the TP53wt NK-AML were susceptible to a combination treatment
with idasanutlin and cobimetinib whereas TP53mut AML cells as well as normal peripheral blood
monocytes and normal CD34 positive selected bone marrow cells were minimally affected.
2.4. Correlation of Cellular FLT3 and MDM2 Protein Levels with Susceptibility to Idasanutlin and Cobimetinib
As there was no apparent correlation of NPM1 gene status with idasanutlin sensitivity in
FLT3wt AML cells, we hypothesized that susceptibility to the MDM2 inhibitor may depend on
the abundance of the target protein in the AML cells. We therefore determined the MDM2 protein
levels in AML blast cells as well as in normal peripheral blood mononuclear cells (PBMC) and in
normal hematopoietic stem cells (HSC). MDM2 protein levels ranged from 2 ng/µg to 25 ng/µg
(MDM2/GAPDH), with highest levels observed in the stem cell samples. Low MDM2 levels were
present in normal PBMC as well as in idasanutlin-resistant AML cells. Compared to PBMC and
idasanutlin-resistant cells, idasanutlin-sensitive NK-AML cells had elevated MDM2 protein levels
with median levels of 7 versus 3.5 ng/µg (Figure 6A). The median MDM2 levels in sensitive and
resistant subgroups were 8 versus 4 ng/µg, and 10 versus 3 ng/µg in FLT3wt and FLT3-ITD NK-AML
respectively. Surprisingly, cobimetinib-sensitive AML cells also had elevated MDM2 levels with
8 versus 5 ng/µg, indicating that NK AML cells with elevated MDM2 levels may be particularly
susceptible to the combined treatment with idasanutlin and cobimetinib.
As FLT3 signaling activity may correlate to MDM2 protein levels and MEK activity, we also
determined the FLT3 protein levels in all samples. Indeed, there was a strong correlation of
FLT3 and MDM2 levels (Figure S6). FLT3 levels ranged from 1 to 120 ng/µg (FLT3/GAPDH)
with highest levels in the normal CD34 positive stem cells (Figure 6B). Low FLT3 levels were
present in normal PBMC as well as in idasanutlin-resistant AML cells. Compared to PBMC and
idasanutlin-resistant cells, idasanutlin-sensitive NK-AML cells had elevated FLT3 protein levels with
median levels of 25 versus 12 ng/µg. The median FLT3 levels in sensitive and resistant subgroups
were 28 versus 4 ng/µg, and 26 versus 13 ng/µg in FLT3wt and FLT3-ITD NK-AML, respectively.
Cobimetinib sensitive AML cells also had elevated FLT3 levels (32 versus 16 ng/µg) indicating that
NK AML cells with elevated FLT3 levels may be particularly susceptible to the combined treatment
with idasanutlin and cobimetinib.
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3. Discussion
The aim of this study was to identify AML subgroups with particular sensitivity to the combined
treatment with the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib. We assessed
the two inhibitors as single agents and in combination treatments in a variety of AML cell lines and in
a variety of AML patient leukemic cells for their ability to induce apoptosis and cell death. As MDM2
inhibition can only be effective in a TP53 wild type setting TP53 mutated AML cells were, in fact,
not susceptible to idasanutlin treatment. Interestingly, however, only half of the TP53wt AML cells were
susceptible to idasanutlin. Idasanutlin had a greater effect on FLT3-ITD than on FLT3wt cells, while the
presence of a NPM1 mutation had no effect on MDM2 inhibitor sensitivity. Similar correlations
have previously been described for other MDM2 inhibitors [19]. Sensitivity to idasanutlin treatment
appeared to be limited to AML subgroups characterized by MDM2 overexpression, whereas idasanutlin
resistance was observed in AML subgroups characterized by MDMX overexpression [20].
It was to some extent unexpected that sensitivity to the MDM2 inhibitor was not affected in
the presence of mutated NPM1 (NPMc) which has lost the ability to stabilize the tumor suppressor
p53 in the nucleus and may inhibit p53 by cytoplasmic retention. Apparently, the presence of reduced
levels of normal NPM1 protein can provide adequate stabilization of p53 to induce cell cycle arrest
and apoptosis in idasanutlin treated NPM1 mutated AML cells. However, we found that both FLT3
and MDM2 expression levels appear to be adequate biomarkers to predict response of AML cells to
idasanutlin. Supporting evidence for MDM2 expression as a predictive marker came from a phase I
study with idasanutlin where AML patients with elevated MDM2 protein expression had improved
outcomes [21]. The molecular mechanisms underlying the correlation of MDM2 protein levels and
response to MDM2 inhibitors may be related to the phenomenon of oncogene addiction where the
tumor relies on a dominant oncogene or mechanism for growth and survival, so that inhibition of this
specific oncogene/pathway is sufficient to halt the neoplastic phenotype [22,23].
Similar to idasanutlin, not all AML cells were sensitive to the MEK1 inhibitor cobimetinib.
Notably, RAS mutated cells were more susceptible to cobimetinib than RAS wild type cells. Here the
molecular mechanism is, in all likelihood, an addiction to the RAS oncogene. In addition to RAS-
mutated cells, FLT3wt cells were generally more susceptible to cobimetinib than FLT3-ITD cells.
Most likely, wild type FLT3 receptor signaling is more dependent on MEK activity than FLT3-ITD
receptor signaling. FLT3-ITD mutants induce auto-phosphorylation of the receptor, interleukin
3-independent growth and a strong STAT5 and mitogen-activated protein kinase (MAPK) activation.
In contrast to the FLT3-ITD mutants, ligand stimulated FLT3 wild-type receptors activate AKT and
MAPK, but not STAT5 [10]. Thus, the acquisition of FLT3-ITD ensures leukemic stem cell survival
by up-regulating MCL-1 gene expression via constitutive STAT5 activation that is independent of
wild-type FLT3 signaling [24].
Surprisingly, susceptibility to cobimetinib did not strictly correlate to the mutational status of
RAS genes, but, unexpectedly, to FLT3 and MDM2 protein levels. RAS mutant cell lines OCI-AML3,
HL-60 and PL-21 as well as RAS mutated AML patient samples showed sensitivity to cobimetinib,
as well as AML cells with normal RAS genes like OCI-AML2 and a subset of the AML patient samples
with normal RAS status. In studies with other MEK inhibitors there was also no strict correlation of
the responses with the mutational or phosphoprotein status of RAS or RAF [25]. However, it was
described that different compensatory RAS effectors including PI3K can mediate resistance to MEK
inhibitors. In any case, our data indicate that FLT3 and MDM2 expression may be adequate biomarkers
to predict response of AML cells not only to idasanutlin, but also to cobimetinib.
How can activated RAS lead to p53 inhibition in AML cells? RAS can have opposing effects on
p53 [20]. Levels of p53 are determined by opposing effects of ARF and MDM2. In a variety of primary
cells activated oncogenic RAS leads to p53 induction via induction of the MDM2 inhibitor ARF [20].
In AML cells, activated (normal) RAS can induce MDM2 via MEK and ERK and thereby inhibit
p53. Perhaps activated RAS is unable to induce ARF in AML cells? Indeed NPM1 overexpression
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can antagonize ARF function while increasing its nucleolar localization [26] and ARF appears to be
inactivated in NPM1 mutated AML cells [27].
Susceptibility to the combination treatment with cobimetinib and idasanutlin was present in AML
cells defined by normal karyotype (NK) and wild type status of the TP53 gene with elevated FLT3 and
MDM2 protein levels. The correlation of FLT3 and MDM2 levels and sensitivity to both idasanutlin and
cobimetinib in AML cells may be based on these molecular mechanisms: MDM2 levels can be induced
by FLT3 and FLT3-ITD via AKT, but also by activated RAS via MEK and ERK [28], while MDM2 mRNA
export from the nucleus is dependent on MEK and MNK1 activity [29]. Thus, elevated MEK, ERK and
MNK1 activities induce high levels of MDM2 protein leading to p53 inhibition and cell proliferation in
AML cells. Treatment with cobimetinib and idasanutlin may have synergistic effects on viability of
AML cells with elevated FLT3 and MDM2 levels by concomitant inhibition of MEK and MDM2.
Synergistic effects on cell viability with idasanutlin and cobimetinib were present particularly
in OCI-AML2, MV4-11 and MOLM-13 cells and in several FLT3wt and FLT3-ITD patient samples
with elevated FLT3 and MDM2 protein levels. Synergistic effects were present in MV4-11 cells,
particularly regarding CDKN1A gene induction, and in MOLM-13 cells, particularly regarding
MCL1 gene inhibition and apoptosis induction. As there is independent regulation of MCL-1 gene
expression by p53 and by MEK, inhibiting both MDM2 and MEK can have synergistic effects on
MCL1 gene expression. In contrast, cobimetinib treatment had negative effects on the idasanutlin
induced CDKN1A gene expression in OCI-AML2 cells. Single compound treatment with idasanutlin or
with cobimetinib can induce CDKN1A gene expression in OCI-AML2 cells indicating that regulation
of CDKN1A gene expression by p53 and MEK is dependent in this cell line. Consequently, idasanutlin
and cobimetinib can separately induce the downstream effect of CDKN1A induction such as G1
cell cycle arrest followed by cell cycle exit in OCI-AML2 cells, with an enhanced effect in the
combination treatment.
Synergistic effects on cell viability with idasanutlin and cobimetinib were present independent of
the sequence of application, indicating that the order of target inhibition for MEK1 and MDM2 was not
important. Sequential application of idasanutlin and cobimetinib had the same effects on cell viability
as direct combination treatment. Pretreatment with one inhibitor did not enhance the susceptibility
of AML cells to the second inhibitor. This allows several treatment regimens available for testing in
a possible future clinical trial.
Our data indicate that the combination of idasanutlin and cobimetinib may be an effective
and specific treatment to target NK-AML with wild type TP53 and elevated FLT3 and MDM2
levels. Within a clinical trial, FLT3 and/or MDM2 protein levels in the blast cells may allow patient
stratification; therefore, FLT3 and MDM2 cytometry with peripheral blood leukocytes may be required
to support treatment decisions. In the future, it may be feasible to do a full array of treatment response
assays including p53 target gene induction in a high-speed setup before starting therapy. NK-AML with
low FLT3 and MDM2 levels may be treated by targeting other regulators of the p53 function frequently
overexpressed in AML like MDMX, XPO1 and CUL9/PARC [5]. Combination treatments with more
than two targeted compounds may increase therapeutic specificity and efficacy and become prevalent
in the near future. Moreover, AML patients fit for intensive therapy may profit from combination
treatments with targeted compounds and conventional chemotherapy.
4. Materials and Methods
4.1. Cell Lines
OCI-AML2 (FLT3wt, TP53wt), OCI-AML3 (FLT3wt, NPM1L287fs, NRASQ61L, TP53wt),
MOLM-13 (FLT3ITD, t(9;11), TP53wt), MV4-11 (FLT3ITD, t(4;11), TP53wt), PL-21 (FLT3P336L,
KRASA146V, TP53P36fs), HL60 (FLT3wt, TP53del) and MOLM-16 (FLT3wt, TP53V173M, TP53C238S)
cell lines were supplied by the Leibniz Institute DSMZ, German Collection of Microorganisms and
Cell Cultures (Braunschweig, Germany). AML cells were grown in RPMI 1640 (SIGMA-ALDRICH,
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St. Louis, USA) supplemented with 20% fetal bovine serum (FBS, Biochrom GmbH, Germany).
Cells were passaged for a minimal number of times between thawing and use in the
described experiments.
4.2. Patient Samples
Mononuclear cells of AML patients diagnosed and treated at the University Hospital,
Bern, Switzerland between 2015 and 2016 were included in this study. Informed consent of all
patients in the study was obtained according to the Declaration of Helsinki, and the studies were
approved by decisions of the local ethics committee of Bern, Switzerland. Mutational screenings for
FLT3, NPM1, TP53 genes and conventional karyotype analysis of at least 20 metaphases were performed
for each patient. Peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells
(BMMCs) were collected at the time of diagnosis before treatment start.
4.3. Methods
Description of the methods in the supplements: Measurement of mRNA expression by qPCR,
DNA fragmentation assay, Flow cytometry, Imaging cytometry, Measurement of protein levels by
Western Blot and Enzyme-linked immunosorbent Assay (ELISA).
5. Conclusions
AML cells with normal karyotype (NK) and wild type status of TP53 with elevated FLT3 and
MDM2 protein levels emerge to be susceptible to the combined treatment with the MEK1 inhibitor
cobimetinib and the MDM2 inhibitor idasanutlin. FLT3 and MDM2 are biomarkers for treatment
response to idasanutlin and cobimetinib in AML. This preclinical study might provide the rationale for
initiating a clinical study in TP53wt NK-AML patients unfit for intensive chemotherapy evaluating
this treatment combination.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/6/170/s1,
Supplemental Methods: Cytotoxicity assays, Measurement of mRNA expression by qPCR, DNA fragmentation
assay, Flow cytometry, Measurement of protein levels by Western Blot, Enzyme-linked immunosorbent Assay
(ELISA), Figure S1: Synergistic effect on cell viability in OCI-AML2 cells treated with idasanutlin and cobimetinib
independent of sequence of drug application. Cell viability measurements in cells pretretead for 6 h and treated
for 24 h with idasanutlin and cobimetinib in all combinations. Idasanutlin pretreatment followed by cobimetinib
treatment had the same effect on cell viability as cobimetinib pretreatment followed by idasanutlin treatment.
Moreover, both sequential treatments had nearly the same effect on cell viability as 30 h of direct combination
treatment, Figure S2: Induction of the tumor suppressor protein p53 and the cell cycle inhibitor CDKN1A gene
in MV4-11 cells treated with idasanutlin and cobimetinib. Western blot for p53 and b-actin (A) and quantitative
PCR for CDKN1A mRNA normalized to GAPDH mRNA (B) in MV4-11 cells treated with the indicated amounts
of idasanutlin and cobimetinib, Figure S3: Induction of BAX gene expression and apoptosis in OCI-AML2 cells
treated with idasanutlin and cobimetinib. Quantitative PCR for BAX mRNA normalized to GAPDH mRNA
(A) and imaging cytometry for annexin positive cells (B) in OCI.AML2 treated with the indicated amounts of
idasanutlin and cobimetinib, Figure S4: Induction of cell cycle exit and cell death in OCI-AML2 and MOLM-13
cells treated with idasanutlin and cobimetinib. Cell cycle analysis by flow cytometry measurements of DNA
content (DAPI) and proliferation marker Ki-67 in OCI-AML2 (A) and MOLM-13 (B) treated with the indicated
amounts of idasanutlin and cobimetinib, Figure S5: Induction of caspase 3/7 activity and apoptosis in MOLM-13
cells treated with idasanutlin and cobimetinib. Cell analysis by imaging cytometry of caspase 3/7 activity (A) and
apoptosis (B) in MOLM-13 cells treated with the indicated amounts of idasanutlin and cobimetinib. Figure S6:
Correlation of FLT3 and MDM2 protein levels in AML and normal leukocytes. MDM2 and FLT3 protein levels
in cellular extracts of AML patient and normal leukocytes as determined by ELISA and normalized to GAPDH,
Table S1: Genetic variants and drug responses in AML cell lines and patient samples.
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Abbreviations
AML acute myeloid leukemia
FLT3 FMS like tyrosine kinase 3
ITD internal tandem duplication
TP53 tumor suppressor p53
MDM2 mouse double minute 2 homolog
MEK mitogen-activated protein kinase kinase
NPM1 nucleophosmin
RAS rat sarcoma protein
GAPDH glyceraldehyde 3-phosphate dehydrogenase
wt wild type
mut mutated
del deleted
fs frame shift
idasa idasanutlin
cob cobimetinib
NK normal karyotype
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